Advocacy intelligence hub — real-time data for patient organizations
Duraclon: FDA approved
In combination with opiates for the treatment of severe pain in cancer patients that is not adequately relieved by opioid analgesics alone.
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Duraclon
(Clonidine)Orphan drugRoxane Laboratories, Inc.
Mechanism of Action Epidurally administered clonidine produces dose-dependent analgesia not antagonized by opiate antagonists. The analgesia is limite...
Browse all Congenital insensitivity to pain with severe intellectual disability news →
View all Congenital insensitivity to pain with severe intellectual disability specialists →